Effect of pioglitazone on atherogenic outcomes in type 2 diabetic patients: A comparison of responders and non-responders

Diabetes Research and Clinical Practice

Volumn 77, Issue 3, 2007, Pages 389-398

  Igarashi, Masahiko ^a   Jimbu, Yumi ^a   Kimura, Minako ^a   Hirata, Akihiko ^a   Yamaguchi, Hiroshi ^a   Tominaga, Makoto ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

Diabetes mellitus; Lp (a); Pioglitazone; Responder; RLP C

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CHOLESTEROL; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIPID BLOOD LEVEL; LIPID METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE;

AGED; ATHEROSCLEROSIS; BODY MASS INDEX; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 34547654459     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2006.12.022     Document Type: Article

References (50)

1. Kannel W.B., and McGee D.L. Diabetes and cardiovascular disease, the Framingham study. JAMA 241 (1979) 2035-2038
2. Haffner S.M., Lehto S., Rönnemaa T., Pyörälä K., and Laakso M. Mortality from coronary heart diseases and in non-diabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339 (1998) 229-234
3. Purnell J.Q., Hokanson J.E., Marcovina S.M., Steffes M.W., Cleary P.A., and Brunzell J.D. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure. JAMA 280 (1998) 140-146
4. Reaven G.M. Role of insulin resistance in human disease. Diabetes 37 (1998) 1595-1606
5. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., Hadden D., Turner R.C., and Holman R.R. Association of glycaemia with macrovascular and micro-vascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 321 (2000) 405-412
6. Tominaga M., Eguchi H., Manaka H., Igarashi K., Kato T., and Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes study. Diabetes Care 22 (1999) 920-924
7. DECODE Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-h diagnostic criteria. Ann. Intern. Med. 161 (2001) 397-405
8. Hofmann C.A., and Colca J.R. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabetes Care 15 (1992) 1075-1078
9. Suter S.L., Nolan J.J., Wallace P., Gumbiner B., and Olefsky J.M. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15 (1992) 193-203
10. Fonseca V.A., Valiquett T.R., Huang S.M., Ghazzi M.N., and Whitecomb R.W. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group. J. Clin. Endocrinol. Metab. 83 (1998) 3169-3176
11. Aronoff S., Rosenblatt S., Braithwaite S., Egan J.W., Mathisen A.L., Schneider R.L., et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care 23 (2000) 1605-1611
12. Kipnes M.S., Krosnick A., Rendell M.S., Eagan J.W., Mathisen A.L., and Schneider R.L. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am. J. Med. 111 (2001) 10-17
13. Minamikawa J., Tanaka S., Yamauchi M., Inoue D., and Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J. Clin. Endocrinol. Metab. 83 (1998) 1818-1820
14. Takagi T., Yamamuro A., Tamita K., Yamabe K., Katayama M., Morioka S., et al. Impact of troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus. Am. J. Cardiol. 89 (2002) 318-322
15. Choi D., Jang Y., Kim S.K., Lim S.K., Choi S.H., Lee H.C., et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 27 (2004) 2654-2660
16. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. PROactive investigators, secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
17. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkinson W.O., Willson T.M., and Kliewer S.A. An antidiabetic thiazolinedione is a high-affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). J. Biol. Chem. 270 (1995) 12953-12956
18. Devaraj S., Vega G., Lange R., Grundy S.M., and Jialal I. Remnant-like particle cholesterol levels in patients with dysbetalipoproteinemia or coronary artery disease. Am. J. Med. 104 (1998) 445-450
19. McNamara J.R., Shah P.K., Nakajima K., Cupples L.A., Wilson P.W., Ordovas J.M., et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: result from the Framingham Heart Study. Atherosclerosis 154 (2001) 229-236
20. Chiarugi L., Prisco D., Antonucci E., Capanni M., Fedi S., Liotta A.A., et al. Lipoprotein (a) and anticardiolipin antibodies are risk factors for clinically relevant restenosis after elective balloon percutaneous transluminal coronary angioplasty. Atherosclerosis 154 (2001) 129-135
21. Duriez P., Dallongeville J., and Fruchart J.C. Lipoprotein(a) as a marker for coronary heart disease. Br. J. Clin. Pract. Suppl. 77A (1996) 54-61
22. Nakajima K., Saito T., Tamura A., Suzuki M., Nakano T., Adachi M., et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti A-I immunoaffinity mixed gels. Clin. Chim. Acta 223 (1993) 53-71
23. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
24. Kuehnle H.F. New therapeutic agents for the treatment of NIDDM. Exp. Clin. Endocrinol. Diabetes 104 (1996) 93-101
25. Satoh N., Ogawa Y., Usui T., Tagami T., Kono S., Uesugi H., et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26 (2003) 2493-2499
26. Araki T., Emoto M., Yokoyama H., Motoyama K., Morioka T., Tahara H., et al. Insulin resistance index as a predictor for pioglitazone treatment in type 2 diabetes. Osaka City Med. J. 51 (2005) 19-25
27. Blüher M., Lübben G., and Paschke R. Analysis of the relationship between the Pro12Ala variant in the PPAR-γ2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. Diabetes Care 26 (2003) 825-831
28. Gavin L.A., Barth J., Arnold D., and Shaw R. Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control. Endocr. Pract. 6 (2000) 305-310
29. Inzucchi S.E., Maggs D.G., Spollett G.R., Page S.L., Rife F.S., Walton V., et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N. Engl. J. Med. 338 (1998) 867-872
30. Turner R.C., Millns H., Neil H.A., Stratton I.M., Manley S.E., Matthews D.R., et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). Br Med J 316 (1998) 823-828
31. Collins R., Armitage J., Parish S., Sleight P., Peto R., and Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363 (2004) 757-767
32. Colhoun H.M., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
33. Iso H., Naito Y., Sato S., Kitamura A., Okamura T., Sankai T., et al. Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am. J. Epidemiol. 153 (2001) 490-499
34. Jeppesen J., Hein H.O., Suadicani P., and Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 97 (1998) 1029-1036
35. Couch S.C., Isasi C.R., Karmally W., Blaner W.S., Starc T.J., Kaluski D., et al. Predictors of postprandial triacylglycerol response in children: the Columbia University Biomarkers Study. Am. J. Clin. Nutr. 72 (2000) 1119-1127
36. Derosa G., Cicero A.F., Gaddi A., Ragonesi P.D., Fogari E., Bertone G., et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin. Ther. 26 (2004) 744-754
37. Goldberg R.B., Kendall D.M., Deeg M.A., Buse J.B., Zagar A.J., Pinaire J.A., et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28 (2005) 1547-1554
38. Phillips N.R., Waters D., and Havel R.J. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 88 (1993) 2762-2770
39. Tomono S., Kawazu S., Kato N., Ono T., Ishii C., Ito Y., et al. Uptake of remnant-like particles (RLP) in diabetic patients from mouse peritoneal macrophages. J. Atheroscler. Thromb. 1 (1994) 98-102
40. Ai M., Tanaka A., Ogita K., Sekine M., Numano F., and Reaven G.M. Relationship between plasma insulin concentration and plasma remnant lipoprotein response to an oral fat load in patients with type 2 diabetes. J. Am. Coll. Cardiol. 38 (2001) 1628-1632
41. Igarashi M., Hirata A., Yamauchi T., Yamaguchi H., Tsuchiya H., Ohnuma H., et al. Clinical utility and approach to estimate postprandial hypertriglycemia by a newly designed oral fat-loading test. J. Atheroscler. Thromb. 10 (2003) 314-320
42. Ginsberg H.N. Insulin resistance and cardiovascular disease. J. Clin. Invest. 106 (2000) 453-458
43. Pakala R., Kuchulakanti P., Rha S.W., Cheneau E., Baffour R., and Waksman R. Peroxisome proliferator-activated receptor γ: its role in metabolic syndrome. Cardiovasc. Radiat. Med. 5 (2004) 97-103
44. Majali K.A., Cooper M.B., Staels B., Luc G., Taskinen M.R., and Betteridge D.J. The effect of sensitization to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients. Diabetologia 49 (2006) 527-537
45. Danesh J., Collins R., and Peto R. Lipoprotein(a) and coronary heart disease: meta-analysis of prospective studies. Circulation 102 (2000) 1082-1085
46. Kronenberg F., Kronenberg M.F., Kiechl S., Trenkwalder E., Santer P., Oberhollenzer F., et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation 100 (1999) 1154-1160
47. Matsumoto K., Miyake S., Yano M., and Tominaga Y. Increase of lipoprotein (a) with tro-glitazone. Lancet 350 (1997) 1748-1749
48. Ovalle F., and Bell D.S. Troglitazone's effect on lipoprotein (a) levels. Diabetes Care 22 (1999) 859-860
49. Matsumoto K., Miyake S., Yano M., Ueki Y., and Tominaga Y. Relationship between apoprotein (a) phenotype and increase of lipoprotein (a) by troglitazone. Metabolism 48 (1999) 1-2
50. Saely C.H., Koch L., Schmid F., Marte T., Aczel S., Langer P., et al. Lipoprotein(a), type 2 diabetes and vascular risk in coronary patients. Eur. J. Clin. Invest. 36 (2006) 91-97